ArticleHematological oncology2022

Adult patients with Ph+ ALL benefit from conditioning regimen of medium-dose VP16 plus CY/TBI.

Mari Morita-Fujita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.